ANI Pharmaceuticals
Quarterly Financials
| Values in thousands | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
Revenue | $211,371 | $197,122 | $190,574 | $148,332 |
Gross Profit | 113,475 | 124,085 | 110,294 | 85,257 |
EBITDA | 42,028 | 50,985 | 14,852 | -13,419 |
EBIT | 18,747 | 28,094 | -7,747 | -29,167 |
Net Income | 7,730 | 15,681 | -10,276 | -24,166 |
Net Change In Cash | 211,371 | 197,122 | 190,574 | 148,332 |
Free Cash Flow | 75,812 | 15,145 | 13,380 | 7,031 |
Cash | 217,797 | 149,802 | 144,861 | 144,982 |
Basic Shares | 20,308 | 20,046 | 19,445 | 19,404 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $614,376 | $486,816 | $316,385 | $216,136 |
Gross Profit | 364,166 | 305,303 | 177,600 | 115,526 |
EBITDA | 79,147 | 106,599 | 33,919 | -1,684 |
EBIT | 11,416 | 46,808 | -25,734 | -48,936 |
Net Income | -18,522 | 18,779 | -47,896 | -42,603 |
Net Change In Cash | 614,376 | 486,816 | 316,385 | 216,136 |
Cost of Revenue | -52,067 | 92,434 | ||
Free Cash Flow | 47,064 | 100,448 | -47,658 | -20,316 |
Cash | 144,861 | 221,121 | 48,228 | 100,300 |
Basic Shares | 19,318 | 18,194 | 16,260 | 12,596 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-09-30 | $0 |
2025-06-30 | $1.80 |
2025-03-31 | $0.69 |
2024-12-31 | -$0.55 |
